NUMIF

Numinus Wellness Inc.

Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment

Approval Marks Numinus' First use of Psilocybin-Assisted Therapy Treatment Outside of Clinical Trials VANCOUVER, BC, May 16, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Health Ca... Read More...

Numinus to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022

VANCOUVER, BC, May 11, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a fireside chat hosted by Patrick Trucchio, H.... Read More...

Numinus to Participate in Maxim’s 2022 Virtual Growth Conference on March 28-30, 2022

VANCOUVER, BC, March 15, 2022 -ย Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Maxim Group's 2022 Virtual Growth Conference to be held virtually on March 28-30, 20... Read More...

Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

VANCOUVER, BC, Feb. 28, 2022 -ย Numinus Wellness Inc. ("Numinus") (TSX: NUMI)ย (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"), held earli... Read More...

Numinus Wellness Inc. Graduates to the OTCQX Best Market

VANCOUVER, BC, Jan. 26, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it will commence trading on the OTCQXยฎ Best Market in the United States when the market opens tomorro... Read More...

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

The trial evaluates Numinus' first trademarked product and patent-pending production process VANCOUVER, BC, Jan. 14, 2022 -ย Numinus Wellness Inc.ย ("Numinus") (TSX:ย NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally submitted the clinical trial application ("CTA") to Health Canada for its... Read More...

Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders

VANCOUVER, BC, Jan. 13, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today that its annual general meeting of shareholders (the "AGM"), which was originally scheduled to be held on Friday, January 21, 20... Read More...

Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines

Policy amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis VANCOUVER, BC, Dec. 22, 2021 - Numinus Wellness Inc.ย ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare,ย commends Health Canada's leadership for amending th... Read More...

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Analytical testing will accelerate Numinus' Research and Development capabilities and generate revenue through third-party clients VANCOUVER, BC, Nov. 29, 2021 - Numinus Wellness Inc.ย ("Numinus") (TSXV:ย NUMI), a leader in psychedelics-focused mental healthcare, has today announced novel, proprietary methods for psychedelic mushroom compo... Read More...

Numinus Announces Departure of Stacey Wallin

VANCOUVER, BC, Nov. 25, 2021 -ย Numinus Wellness Inc.ย ("Numinus") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today following the conclusion of several weeks of discussions that Stacey Wallin, former Chief Strategy Officer, is no longer with t... Read More...